Management Team

Jim Hollingshead

President & Chief Executive Officer

Jim Hollingshead brings more than three decades of global leadership experience across medtech and life sciences, with a career distinguished by the successful launch and scale-up of category-defining products. Before joining BVI, Jim twice led transformative companies, achieving top market share, sustained profitable growth, and meaningful improvements in patients’ lives. As President and CEO of Insulet Corporation from 2022 to 2025, after first joining as an Independent Director, Jim drove the launch of revolutionary technologies that leapfrogged competitors and positioned Insulet as the #1 player in its category. His leadership combined product vision with commercial rigor, translating innovation into rapid market adoption.

Prior to Insulet, Jim held senior executive roles at ResMed, including President of the Sleep and Respiratory Care business, President of the Americas, Chief Strategy Officer, and President of Ventures & Initiatives. There, he led the conceptualization and launch of cloud-based offerings that redefined connected care and reshaped the industry’s competitive landscape. Jim began his career in strategy consulting, advising global organizations across multiple industries, and today serves on the Board of Vantive, a leading kidney care medtech company. He holds a BA from Stanford University and a master’s and Ph.D. from UC Berkeley.

Andrew Chang

Chief Commercial Officer

Andrew Chang brings over 20 years of commercial leadership experience in the ophthalmic medical device and pharmaceutical sectors, having held senior roles across some of the industry’s most recognized global organizations.

Chang began his career in finance and early-stage business roles before transitioning into the ophthalmic space, where he held progressive commercial leadership positions at ISTA Pharmaceuticals and later Bausch + Lomb. During his time at ISTA, he helped drive the successful introduction of multiple ophthalmic pharmaceutical products. Following the acquisition of ISTA by Bausch + Lomb, he took on broader responsibilities at OptiMedica which sold to Abbott Medical Optics shortly after. Eventually he served as General Manager and Senior Vice President for Bausch + Lomb Surgical, overseeing U.S. sales, marketing, operations, and business development.

He later joined ZEISS Medical Technology, where he served as President of Carl Zeiss Meditec USA, Inc. and Head of Global Sales for Ophthalmic Devices. In this role, he led global commercial strategy and market execution across a broad portfolio of diagnostic and surgical technologies, playing a key role in expanding ZEISS’s global footprint and driving sustained commercial growth.

Beyond his executive leadership roles, Andrew is a passionate advocate for innovation in ophthalmology. He currently serves on industry and advisory boards the ASCRS Foundation, the Ophthalmology Foundation, Medical Device Manufacturers Association (MDMA), CEDARS/ASPENS Industry Committee, AECOS Executive Committee, Ophthalmic World Leaders (OWL), EyeSustain and is a founding member of the Vanguard Ophthalmology Society. In the past he served on the board of MicroOptx, President and board of FCI Ophthalmics Inc / FCI SAS, and American Glaucoma Society Foundation.

Andrew Chang earned his Bachelor of Science degree in Management from Rutgers University – Newark

Andrew (Andy) Dawson

Chief People Officer and Head of Corporate Affairs

Andrew (Andy) Dawson brings more than 20 years of experience in human resource strategy and management with some of the world’s leading Healthcare and Biopharma companies. Mr. Dawson started his career in Human Resources with Eli Lilly and Company and continued to grow his career through progressive HR leadership roles at both Novartis and Roche around the globe, including the formation of the Vaccines and Diagnostics Business following Novartis’ acquisition of Chiron. Upon joining Shire in 2014, he played a key leadership role in re-imagining the global HR function during a significant time of transformation. While there, he helped lead the organization through significant change and growth following numerous mergers and acquisitions including the leadership of the new global site strategy following the $32bn acquisition of Baxalta, and the design and execution of the new organization design for the expanded company. Following this, Mr Dawson held roles of increasing scope and responsibility at TripAdvisor and most recently leading the Human Resources function for emerging, pre-commercial companies in the Biotech space. Mr Dawson is a member of the Forbes HR Leadership Council, serves on the advisory board(s) for LEAP HR and BioPharma Talent / CBI. Mr Dawson holds a Masters Degree in Human Resources Management and Development from the University of Salford (Manchester, UK).

Mikhail Boukhny

Chief Technology Officer

Mikhail Boukhny brings over 25 years of leadership experience in Surgical Ophthalmology. Until 2018 he lead Alcon’s Surgical Instrumentation R&D in Cataract, Vitreoretinal, Refractive and Diagnostics areas. Mikhail has grown through the ranks at Alcon, developing many breakthrough products, including Torsional ultrasound and Centurion Vision System. He combines a  deep understanding of unmet clinical and business needs with the ability to bring breakthrough innovation to commercial success as well as to create strong teams. Mikhail holds over 70 patents; while at Alcon he was repeatedly recognized for his accomplishments,  including the prestigious Novartis VIVA award. Most recently Mikhail was leading Zeiss MediTec Surgical R&D, Ophthalmology where, in addition to equipment, he was responsible for IOLs, IOL delivery systems and OVDs. Dr. Boukhny received his M.S. in Biophysics from the Moscow Institute of Physics and Technology and his Ph.D. in Physics from the University of Virginia.

Jean-Nicolas Fassin

Senior Vice President, Business Development & General Counsel

Jean-Nicolas (“JN”) Fassin has 20 years of experience in M&A, corporate finance, strategy and law. He joined the BVI leadership team following the acquisition of PhysIOL^® by BVI in late 2018. Prior to joining PhysIOL® in 2017, JN was a Senior Manager at BDO Corporate Finance in Belgium advising clients on small- and mid-sized M&A transactions, valuation and financial due diligence across various industries.  He also worked as management consultant at McKinsey & Company focusing on strategy assignments and as lawyer in top tier law firms advising clients on M&A, litigation and corporate law matters.  He has an MBA from London Business School, an LLM from Columbia Law School and is a graduate of Sciences Po Paris and the University of Liège, Faculty of Law.